NIH R01 · 2025
Afferent Mechanisms of Vagal Neuromodulation Therapy
1 Project Summary 2 3 Vagal nerve stimulation (VNS) therapy is approved for three central nervous system disorders. Despite promising 4 preclinical evidence of success amelioration of heart failure, several large patient trials have failed to meet 5 designated endpoints. Remarkably many recommended clinical protocols for VNS therapy appear to violate 6 strong preclinical evidence as well as approved therapies that rely on vagal afferent activation of central nervous 7 mechanisms. Low intensities of clinically tolerated VNS activate myelinated vagal afferents and these activate 8 neurons within the nucleus of the solitary tract (NTS). Preclinical data on vagal NTS neurons outline multiple 9…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.